HDL Therapeutics Overview

  • Founded
  • 2009
Founded
  • Status
  • Private
  • Employees
  • 2
Employees
  • Latest Deal Type
  • Series E
  • Latest Deal Amount
  • $3.36M
Latest Deal Amount

HDL Therapeutics General Information

Description

Developer of a cardiovascular therapeutic device designed to fight heart disease The company's device uses a patient's own plasma to transform the majority of the circulating alpha HDL into pre-beta particles to re-infuse to the patient to accelerate the removal of lipids from atherosclerotic plaque, wherever it may occur in the cardiovascular circulation, enabling physicians to treat acute coronary syndrome and complement treatment with other lipid-modifying therapies.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Therapeutic Devices
Other Industries
Other Devices and Supplies
Biotechnology
Primary Office
  • 601 21st Street
  • Suite 300
  • Vero Beach, FL 32960
  • United States
+1 (772) 000-0000

HDL Therapeutics Timeline

2018201920202021
Financing Round
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

HDL Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series E) 04-Mar-2021 $3.36M 00.00 Completed Generating Revenue
3. Later Stage VC (Series D) 03-Oct-2019 000 00.000 Completed Generating Revenue
2. Later Stage VC (Series B) 31-Dec-2014 $2.04M $2.97M Completed Generating Revenue
1. Early Stage VC (Series A) 13-Feb-2013 $925K $925K 00.000 Completed Generating Revenue
To view HDL Therapeutics’s complete valuation and funding history, request access »

HDL Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 0,000,000 00.000000 00 00 00 00.000
To view HDL Therapeutics’s complete cap table history, request access »

HDL Therapeutics Executive Team (3)

Name Title Board Seat Contact Info
Michael Matin Co-Founder, Chief Executive Officer & Chairman
D. J. Brignola Chief Financial Officer
Bryan Brewer MD Co-Founder, Chief Scientific Officer & Board Member
To view HDL Therapeutics’s complete executive team members history, request access »

HDL Therapeutics Board Members (3)

Name Representing Role Since
Bryan Brewer MD HDL Therapeutics Co-Founder, Chief Scientific Officer & Board Member 000 0000
Dane Andreeff Self Board Member 000 0000
Michael Matin HDL Therapeutics Co-Founder, Chief Executive Officer & Chairman 000 0000
To view HDL Therapeutics’s complete board members history, request access »

HDL Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial